Nazif YALÇIN
Çukurova Anestezi ve Cerrahi Bilimler Dergisi - 2026;9(2):497-505
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to improve metabolic parameters and may reduce cardiovascular risk profile of individuals diagnosed with obesity and/or type 2 diabetes. This study aimed to evaluate the effects of semaglutide on anthropometric, metabolic, and cardiovascular risk parameters over three months of treatment. Methods: A total of 187 patients received semaglutide therapy and were assessed at baseline (0th month) and after three months (3rd month). Anthropometric measurements, laboratory parameters, and cardiovascular Score-2 were recorded. Changes were analyzed using the Wilcoxon signed-rank test, and percentage changes over the study period were calculated. Results: After three months, considerable declines were observed in body weight (-5.6%, p < 0.001), BMI (-1.9%, p < 0.001), systolic blood pressure (-3.5%, p < 0.001), diastolic blood pressure (-5.6%, p < 0.001), fasting blood glucose (-5.5%, p < 0.001), HbA1c (-7.0%, p < 0.001), and LDL cholesterol (-8.3%, p < 0.001). No significant changes were noted in ALT, AST or creatinine levels. Cardiovascular Score-2 significantly decreased from 8.8 +/- 5.2 to 7.4 +/- 4.7 (p < 0.001). Risk distribution changed markedly, reflecting an expansion of the low-risk group from 27 to 47 alongside a contraction of the high-risk group from 83 to 46. Conclusions: Three months of semaglutide treatment significantly improved metabolic parameters and resulted in a favorable decline in cardiovascular risk among patients. Collectively, the data point toward a beneficial cardiovascular impact of GLP-1 RAs in real-world practice.
